Consequently, we successfully retrieved CPMs comprising CNVs, genomic mutations, and medications, characterizing the cancer types: for example, a metastatic breast cancer-related module showing the known relationship among the drug Lapatinib and gene mutations on HER2, and BRCA2, and a skin cancer-related module containing the BRAF-inhibitor PLX4720 and BRAF mutation. This evidence concerns the gene BRAF and skin cancer.